Condition P02
Overweight or obesity without diabetes (adults)
Adults with BMI 27 kg/m2 or higher with at least one weight related condition or BMI 30 kg/m2 or higher (or the Asian thresholds used by the trial) and without diabetes. Includes trials enrolling people with established cardiovascular disease and overweight or obesity.
95 randomized trials; 74 fitted analyses across 25 outcomes.
Headline results
For each primary outcome, the analysis that pools all doses of each medicine, with the three most favorable estimates against the common comparator. Open an analysis for every treatment, dose and check.
All outcomes
Each outcome is analyzed per time window and estimand, with doses kept apart (each dose) and pooled (each medicine). Analyses with too few connected trials are shown as descriptive.
Percent body weight changeprimary
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled | 18 | 6 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately (part 2) | 17 | 14 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled | 13 | 10 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately | 13 | 23 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 6 | 5 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 6 | 14 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Treatment policy | Doses of a drug pooled | 5 | 4 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 5 | 18 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 5 | 7 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Treatment policy | Each dose separately | 5 | 7 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Treatment policy | Each dose separately | 4 | 15 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Treatment policy | Doses of a drug pooled | 4 | 6 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | While on treatment | Each dose separately | 2 | 2 | Pairwise meta-analysis |
| weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 2 | Pairwise meta-analysis |
| weeks 40 to 104 (target week 68) | While on treatment | Doses of a drug pooled | 2 | 2 | Pairwise meta-analysis |
| weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 2 | 2 | Pairwise meta-analysis |
| weeks 104 to 182 (target week 104) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| weeks 20 to 40 (target week 26) | While on treatment | Each dose separately | 1 | 6 | Descriptive only |
| weeks 20 to 40 (target week 26) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 2 | Descriptive only |
Three point MACEprimary
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Cause specific hazards | Each dose separately | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Doses of a drug pooled | 1 | 2 | Descriptive only |
Systolic blood pressure change
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately | 16 | 14 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled | 16 | 6 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled | 7 | 7 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately | 7 | 16 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 4 | 14 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 4 | 6 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 3 | 5 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 2 | Pairwise meta-analysis |
| weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 9 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 2 | 2 | Pairwise meta-analysis |
| weeks 40 to 104 (target week 68) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
| weeks 20 to 40 (target week 26) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 20 to 40 (target week 26) | Treatment policy | Each dose separately | 1 | 6 | Descriptive only |
| weeks 40 to 104 (target week 68) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | While on treatment | Each dose separately | 1 | 5 | Descriptive only |
| weeks 20 to 40 (target week 26) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 20 to 40 (target week 26) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
Weight loss of 5 percent or more
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled | 8 | 6 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately | 8 | 12 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately | 6 | 12 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled | 6 | 6 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Treatment policy | Doses of a drug pooled | 3 | 3 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Treatment policy | Each dose separately | 3 | 6 | Network meta-analysis |
| weeks 104 to 182 (target week 104) | Treatment policy | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | While on treatment | Doses of a drug pooled | 2 | 2 | Pairwise meta-analysis |
| weeks 40 to 104 (target week 68) | While on treatment | Each dose separately | 2 | 2 | Pairwise meta-analysis |
| weeks 104 to 182 (target week 104) | Treatment policy | Each dose separately | 2 | 3 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 20 to 40 (target week 26) | While on treatment | Each dose separately | 1 | 4 | Descriptive only |
| weeks 104 to 182 (target week 104) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 4 | Descriptive only |
| weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
Weight loss of 10 percent or more
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled | 12 | 8 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately (part 2) | 11 | 14 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled | 6 | 6 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately | 6 | 12 | Network meta-analysis |
| weeks 104 to 182 (target week 104) | Treatment policy | Each dose separately | 2 | 3 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Treatment policy | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Treatment policy | Each dose separately | 2 | 6 | Network meta-analysis |
| weeks 104 to 182 (target week 104) | Treatment policy | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 4 | Descriptive only |
| weeks 104 to 182 (target week 104) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
Weight loss of 15 percent or more
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled | 12 | 8 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately (part 2) | 11 | 14 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Treatment policy | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Treatment policy | Each dose separately | 2 | 6 | Network meta-analysis |
| weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled | 2 | 2 | Pairwise meta-analysis |
| weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately | 2 | 5 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 4 | Descriptive only |
| weeks 40 to 104 (target week 68) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
Weight loss of 20 percent or more
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled | 10 | 5 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately (part 2) | 9 | 7 | Network meta-analysis |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
| weeks 104 to 182 (target week 104) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 4 | Descriptive only |
| weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 2 | Descriptive only |
| weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
Weight loss of 25 percent or more
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
SF-36 physical component summary change
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| weeks 20 to 130 (target week 52) | Not stated by the trials | Doses of a drug pooled | 5 | 3 | Network meta-analysis |
| weeks 20 to 130 (target week 52) | Not stated by the trials | Each dose separately | 5 | 9 | Network meta-analysis |
| weeks 20 to 130 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 3 | 3 | Network meta-analysis |
| weeks 20 to 130 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 5 | Network meta-analysis |
| weeks 20 to 130 (target week 52) | Treatment policy | Each dose separately | 2 | 7 | Network meta-analysis |
| weeks 20 to 130 (target week 52) | Treatment policy | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| weeks 20 to 130 (target week 52) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 20 to 130 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| weeks 20 to 130 (target week 52) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
Serious adverse events
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 61 | 32 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 60 | 97 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
Discontinuation due to adverse events
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 25 | 23 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 24 | 59 | Network meta-analysis |
Nausea
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 57 | 31 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 56 | 96 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
Vomiting
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 52 | 95 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 52 | 29 | Network meta-analysis |
Diarrhea
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 54 | 31 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 53 | 96 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
Constipation
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 44 | 80 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 44 | 26 | Network meta-analysis |
Discontinuation due to gastrointestinal adverse events
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 12 | 11 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 9 | 20 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 3 | 3 | Descriptive only |
Gallbladder and biliary disease
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 6 | 6 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 6 | 9 | Network meta-analysis |
Acute pancreatitis
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately (part 2) | 13 | 34 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 13 | 12 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 2 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled | 2 | 2 | Descriptive only |
Medullary thyroid carcinoma
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 5 | 5 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 5 | 11 | Descriptive only |
Thyroid cancer (any)
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 3 | 9 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled | 3 | 3 | Descriptive only |
Suicidal ideation or behavior
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 4 | 4 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 4 | 11 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
Death by suicide
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 17 | 15 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 15 | 33 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 4) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
Pancreatic cancer
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 2 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled | 2 | 3 | Descriptive only |
Any cancer
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 2 | 10 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled | 2 | 6 | Descriptive only |
Acute kidney injury
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 7 | 9 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 7 | 21 | Descriptive only |